Drug Trial Radar · NCT00340080
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
Last checked: Nov 19, 2026Latest source record: Jan 25, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,806
Actual
Start
Apr 2006
Primary completion
Not stated
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the utility of prospective HLA-B\*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable. The study has two (co-primary) objectives: i) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART results in a lower incidence of clinically-suspected HSR versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART, results in a significantly lower incidence of immunologically-confirmed HSR versus current standard of care (no genetic screening or patch testing). The study consists of up to a 28-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected ABC HSR and a subset of ABC-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening). Subjects identified as HLA-B\*5701 positive in the prospective Genetic Screening Arm will not receive ABC and will be excluded from further study. Subjects who experience suspected ABC HSR during the 6-week observation will be withdrawn from ABC-containing product and undergo EPT patch testing 6 weeks later.
Conditions
- HIV Infection
Interventions
AbacavirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of clinically-suspected ABC HSR during the 6-week observation period. Incidence of immunologically-confirmed ABC HSR. The clinical diagnosis of which occurs over the 6-week observation period.
Locations
254 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Miami, Queensland, Australia
GSK Investigational Site
Graz, Austria
GSK Investigational Site
Innsbruck, Austria
GSK Investigational Site
Linz, Austria
GSK Investigational Site
Salzburg, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Bruges, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Aix-en-Provence, France
GSK Investigational Site
Amiens, France
GSK Investigational Site
Angers, France
GSK Investigational Site
Annecy, France
GSK Investigational Site
Avignon, France
GSK Investigational Site
Besançon, France
GSK Investigational Site
Bobigny, France
GSK Investigational Site
Bondy, France
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Cannes, France
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Corbeil-Essonnes, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Dijon, France
GSK Investigational Site
Fréjus, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
La Roche-sur-Yon, France
GSK Investigational Site
La Rochelle, France
GSK Investigational Site
Le Kremlin-Bicêtre, France
GSK Investigational Site
Levallois-Perret, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Marseille, France
Showing 40 of 254 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.